Tag: Pulmonary Arterial Hypertension
tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH
— 6-month GLP-tox study reinforces favorable safety profile of Tiprelestat
— Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026
tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has successfully finalized a comprehensive data package to advance Tiprelestat into a Phase II clinical trial in Pulmonary Arterial Hypertension (PAH) by completing a preclinical GLP-tox study.